After recently receiving the unwelcome news about Hims & Hers Health (NYSE: HIMS) being sued by the U.S. Federal Trade Commission (FTC), California, and Utah, investors were dealt another blow on Monday, Aug. 10.
The telehealth platform, which provides direct-to-consumer (D2C) personal care products and virtual medical services, reported Q2 results, which included its second consecutive earnings miss and its fourth in the past five quarters.